Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥2,900 JPY
Change Today -225.00 / -7.20%
Volume 443.6K
As of 2:00 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

carna biosciences inc (4572) Snapshot

Open
¥2,984
Previous Close
¥3,125
Day High
¥3,065
Day Low
¥2,859
52 Week High
06/26/15 - ¥3,870
52 Week Low
02/5/15 - ¥650.00
Market Cap
25.6B
Average Volume 10 Days
1.2M
EPS TTM
¥-77.23
Shares Outstanding
8.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARNA BIOSCIENCES INC (4572)

Related News

No related news articles were found.

carna biosciences inc (4572) Related Businessweek News

No Related Businessweek News Found

carna biosciences inc (4572) Details

Carna Biosciences, Inc. provides drug discovery supporting products and services; and discovers and develops drugs in Japan. Its drug discovery supporting products and services include kinase proteins; biotinylated kinases to use in the study of kinase-molecule interactions; profiling services; reverse phase protein array cell signaling analysis service to determine whether signaling pathways were affected inside a cell by a kinase inhibitor; live-cell kinase assays that offer tyrosine kinase profiling and screening services; ClariCELL kinase cell-based assay services; and co-crystallography services and crystal grade proteins. The company’s drug discovery supporting products and services also comprise assay development services, such as kinase genetic cloning, kinase protein production, substrate search optimization, and assay optimization services; and protein substrates to use for kinase assays. It also identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using its QuickScout, a kinase drug discovery platform. The company was founded in 2003 and is based in Kobe, Japan.

49 Employees
Last Reported Date: 03/25/15
Founded in 2003

carna biosciences inc (4572) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

carna biosciences inc (4572) Key Developments

Carna Biosciences Announces Collaboration with Johnson & Johnson Innovation

Carna Biosciences announced a worldwide licensing agreement with Janssen Biotech, Inc. to further develop and commercialize compounds from one of Carna Bioscience's small molecule protein kinase inhibitor programs. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, California and Asia Pacific, Carna Biosciences will receive an initial upfront payment and is eligible to receive additional milestone payments upon achievement of certain developmental, regulatory, and commercial milestones. Carna Biosciences will also be eligible to receive tiered royalties on the net sales of commercialized licensed products.

Carna Biosciences, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year Ending December 31, 2015

Carna Biosciences, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of ¥334 million compared to ¥168 million, operating income of ¥98 million compared to operating loss ¥109 million, ordinary income of ¥97 million compared to ordinary loss ¥111 million and net income of ¥94 million or ¥11.30 per share compared to net loss of $111 million or ¥13.50 per share for the last year. The company provided earnings guidance for the year ending December 31, 2015. For the year, the company expects total revenue of ¥917 million and operating income of ¥406 million.

Carna Biosciences, Inc. to Report Q1, 2015 Results on May 11, 2015

Carna Biosciences, Inc. announced that they will report Q1, 2015 results at 3:30 PM, Tokyo Standard Time on May 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4572:JP ¥2,900.00 JPY -225.00

4572 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4572.
View Industry Companies
 

Industry Analysis

4572

Industry Average

Valuation 4572 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.7x
Price/Book 27.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARNA BIOSCIENCES INC, please visit www.carnabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.